Contact
Please use this form to send email to PR contact of this press release:
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
TO:
Please use this form to send email to PR contact of this press release:
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
TO: